Novo Nordisk Levemir Data Shows Weight Loss Advantage Over Sanofi’s Lantus
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies show patients switched to Levemir from Lantus lost weight while improving glycemic control over 26-week period.
You may also be interested in...
Cangene’s Accretropin “Approvable” Pending Resolution Of Manufacturing Issues
Canadian biopharmaceutical firm expects to quickly resolve FDA’s manufacturing concerns for the human growth hormone.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.